MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in treatment-naïve adults with HIV-1 infection. A regulatory filing seeking the approval of DOR/ISL for treating adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy (pre-treated) is already under review...